The major players in the market are GE Healthcare (U.S.), Danaher Corporation (U.S.), PerkinElmer, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), and Becton, Dickinson and Company (U.S.). Some of the other leading players in this market include BioTek Instruments Inc. (U.S.), Bio-Rad Laboratories Inc. (U.S.), Tecan Group Ltd. (Switzerland), Yokogawa Electric Corporation (Japan), and Merck Millipore (U.S.).
For More Informartion: http://www.marketsandmarkets.com/pdfdownload.asp?id=42710391
North America is the largest market for high-content screening, followed by Europe, Asia-Pacific, Latin America, and the Middle East & Africa. High R&D expenditure, the presence of major lifesciences market players, and government support are some of the factors attributed to the large share of North America in the HCS market.
The global high-content screening market is projected to reach USD 909.0 Million by 2022 at a CAGR of 10.3% during the forecast period. The factors expected to drive the growth of the market are growth in funding for cellular research, cost containment in pharma R&D, and technological advancements in HCS solutions. The rapid growth in developing countries across APAC is also expected to provide an opportunity for revenue generation in the market. However, the high cost of HCS instruments and the dearth of knowledgeable and skilled personnel for the operation of the instruments are expected to restrain the market growth.
Based on application, the market is segmented into target identification and validation, primary and secondary screening, toxicity studies, compound profiling, and other applications such as angiogenesis, apoptosis, cell cycle and mitotic index, cell proliferation, endocytosis, protein synthesis, and stem cell differentiation. In 2016, the primary & secondary screening segment dominated the market. The dominant share of this segment is attributed to its wide usage in qualitative assays to exclude the compounds with unintended modes of action, evaluation of bioavailability and lead specificity.
Based on end user, the market is segmented into pharmaceutical & biotechnology companies, academic & government institutes, and contract research organizations. In 2016, the pharmaceutical and biotechnology companies segment accounted for the largest share of the global high-content screening market. The large share of this segment is attributed to the wide usage of HCS in preclinical and clinical studies in the pharmaceutical and biotechnology industries.